Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Subodh Verma, MD, PhD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Promising results with oral Lp(a) inhibitor in phase 2 trial
Tirzepatide reduces HF events in patients with HFpEF and obesity
Milton Packer, MD
Effect of decision support system on early optimization of lipid-lowering therapy
Kausik Ray, MBChB, MD, MPhil
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Chisato Izumi, MD, PhD
Acoramidis reduces all-cause mortality in ATTR-CM
Daniel Judge, MD
Audit and feedback strategy for pharmacists improves HF care
Alexander Sandhu, MD
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
Léna Rivard, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Shawna Nesbitt, MD
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Scott Solomon, MD
Mikhail Kosiborod, MD
HF Management for Patients with Comorbid Conditions
Neil Skolnik, MD
Barry Greenberg, MD
Karina Brown, BSN, RN
Jessica Lin, MPAP
Melissa Mclenon, DNP, ACNP-BC
Optimizing Heart Failure Management
Brian P. McDonough, MD, FAAFP
Trina Huynh, PharmD
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
Level Up Your Skills: Tailoring Management of HF
A Practical Guide to Prescribing in HF
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.